Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 2/20 | 0.32 |
| ▸ | CTSB | P07858 | 2/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4525701 | 0.81 | TSHR (0.31) | LMNACASP1 | |
| SCHEMBL4600207 | 0.81 | TSHR (0.31) | LMNACASP1 | |
| SCHEMBL18881788 | 0.78 | ALDH1A1 (0.34) | CTSLCTSBCTSKALDH1A1LMNA | |
| SCHEMBL2455577 | 0.78 | HRH3 (0.40) | HRH3CTSKALDH1A1L3MBTL1 | |
| SCHEMBL15424523 | 0.77 | — | — | |
| SCHEMBL4599392 | 0.77 | NR1H2 (0.36) | HRH3NR1H2NR1H3ALDH1A1LMNA | |
| SCHEMBL8250067 | 0.76 | ALDH1A1 (0.39) | HRH3ALDH1A1LMNAL3MBTL1HRH4 | |
| SCHEMBL1260149 | 0.75 | — | — | |
| SCHEMBL14827615 | 0.74 | TSHR (0.34) | MME | |
| SCHEMBL19771835 | 0.74 | HRH4 (0.38) | HRH3ALDH1A1LMNAL3MBTL1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910404-B9 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-1910404-B9 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-1910404-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8216999-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8216999-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20090124661-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124661-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7470664-B2 | HCV NS3 protease inhibitors | MERCK & CO., INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470664-B2 | HCV NS3 protease inhibitors | MERCK & CO., INC. (US) | 2008-12-30 | — | — | US | disclosed |
| WO-2007015855-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027071-A1 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME LLC | 2007-02-01 | — | — | US | disclosed |
| US-20070027071-A1 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME LLC | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027071-A1 | HCV NS3 protease inhibitors | HAVCR2, GTF3C3, CTSC | HRH3 4618/4885NR1H2 1166/4885NR1H3 1164/4885 |
| US-20090124661-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | HRH3 4618/4885NR1H2 1166/4885NR1H3 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.